Investigation of AID, Dicer, and Drosha Expressions in Patients with Chronic Lymphocytic Leukemia

References

• Alevizos I, Illei GG. 2010. MicroRNAs as biomarkers in rheumatic diseases. Nat Rev Rheumatol, 6(7),391–398.
   Google Scholar
• Balatti V, Pekarky Y, Rizzotto L, Croce CM. 2013. miR deregulation in CLL. Adv Exp Med Biol, 792, 309–325.
   PubMed Web of Science ®Google Scholar
• Barreto VM, Magor BG. 2011. Activation-induced cytidine deaminase structure and functions: a species comparative view. Dev Comp Immunol, 35(9),991–1007.
   Google Scholar
• Basu U, Franklin A, Schwer B, et al. 2009. Regulation of activation-induced cytidine deaminase DNA deamination activity in B-cells by Ser38 phosphorylation. Biochem Soc Trans, 37(Pt 3), 561–568.
   PubMed Web of Science ®Google Scholar
• Bernstein E, Kim SY, Carmell MA, et al. 2003. Dicer is essential for mouse development. Nat Genet 35(3),215–217.
   PubMed Web of Science ®Google Scholar
• Borchert GM, Holton NW, Larson ED. 2011. Repression of human activation induced cytidine deaminase by miR-93 and miR-155. BMC Cancer, 11, 347.
   PubMed Web of Science ®Google Scholar
• Collado R, Ivars D, Oliver I, et al. 2014. Increased oxidative damage associated with unfavorable cytogenetic subgroups in chronic lymphocytic leukemia. Biomed Res Int, 2014, 686392.
   PubMed Web of Science ®Google Scholar
• Damle RN, Calissano C, Chiorazzi N. 2010. Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells. Best Pract Res Clin Haematol, 23(1),33–45.
   Google Scholar
• Delgado J, Salaverria I, Baumann T, et al. 2014. Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. Haematologica, 99(11),e231–234.
   PubMed Web of Science ®Google Scholar
• Dominguez PM, Shaknovich R. 2014. Epigenetic function of activation-induced cytidine deaminase and its link to lymphomagenesis. Front Immunol, 5, 642.
   PubMed Web of Science ®Google Scholar
• Farooqi AA, Qureshi MZ, Coskunpinar E, et al. 2014. MiR-421, miR-155 and miR-650: emerging trends of regulation of cancer and apoptosis. Asian Pac J Cancer Prev, 15(5),1909–1912.
   PubMedGoogle Scholar
• Ferrajoli A, Shanafelt TD, Ivan C, et al. 2013. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood, 122(11),1891–1899.
   PubMed Web of Science ®Google Scholar
• Francia S, Michelini F, Saxena A, et al. 2012. Site-specific DICER and DROSHA RNA products control the DNA-damage response. Nature, 488(7410),231–235.
   Google Scholar
• Gelmez MY, Teker AB, Aday AD, et al. 2014. Analysis of activation-induced cytidine deaminase mRNA levels in patients with chronic lymphocytic leukemia with different cytogenetic status. Leuk Lymphoma, 55(2),326–330.
   Google Scholar
• Hancer VS, Kose M, Diz-Kucukkaya R, et al. 2011. Activation-induced cytidine deaminase mRNA levels in chronic lymphocytic leukemia. Leuk Lymphoma, 52(1),79–84.
   Google Scholar
• Hasler J, Rada C, Neuberger MS. 2012. The cytoplasmic AID complex. Semin Immunol, 24(4),273–280.
   Google Scholar
• Huemer M, Rebhandl S, Zaborsky N, et al. 2014. AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells. Eur J Immunol, 44(12),3747–3757.
   PubMed Web of Science ®Google Scholar
• Johanson TM, Lew AM, Chong MM. 2013. MicroRNA-independent roles of the RNase III enzymes Drosha and Dicer. Open Biol, 3 (10), 130144.
   Google Scholar
• Karube Y, Tanaka H, Osada H, et al. 2005. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci, 96(2),111–115.
   Google Scholar
• Kumar MS, Lu J, Mercer KL, et al. 2007. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet, 39(5),673–677.
   Google Scholar
• Kumar R, DiMenna LJ, Chaudhuri J, Evans T. 2014. Biological function of activation-induced cytidine deaminase (AID). Biomed J, 37(5),269–283.
   Google Scholar
• Lages E, Ipas H, Guttin A, et al. 2012. MicroRNAs: molecular features and role in cancer. Front Biosci (Landmark Ed), 17, 2508–2540.
   PubMed Web of Science ®Google Scholar
• Lenz G, Staudt LM. 2010. Aggressive lymphomas. N Engl J Med, 362(15),1417–1429.
   Google Scholar
• Livak KJ, Schmittgen TD, 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 25(4),402–408.
   PubMed Web of Science ®Google Scholar
• Marantidou F, Dagklis A, Stalika E, et al. 2010. Activation-induced cytidine deaminase splicing patterns in chronic lymphocytic leukemia. Blood Cells Mol Dis, 44(4),262–267.
   Google Scholar
• Matutes E, Attygalle A, Wotherspoon A, Catovsky D. 2010. Diagnostic issues in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol, 23(1),3–20.
   Google Scholar
• Nagaoka H, Tran TH, Kobayashi M, et al. 2010. Preventing AID, a physiological mutator, from deleterious activation: regulation of the genomic instability that is associated with antibody diversity. Int Immunol, 22(4),227–235.
   Google Scholar
• O’Brien SM, Furman RR, Byrd JC, Smith, A. 2014. Clinical roundtable monograph: unmet needs in the treatment of chronic lymphocytic leukemia: integrating a targeted approach. Clin Adv Hematol Oncol, 12(1 Suppl 3), 1–13.
   Google Scholar
• Orthwein A, Di Noia JM. 2012. Activation induced deaminase: how much and where? Semin Immunol, 24(4),246–254.
   PubMed Web of Science ®Google Scholar
• Palacios F, Moreno P, Morande P, et al. 2010. High expression of AID and active class switch recombination might account for a more aggressive disease in unmutated CLL patients: link with an activated microenvironment in CLL disease. Blood, 115(22),4488–4496.
   Google Scholar
• Peng JC, Karpen GH. 2007. H3K9 methylation and RNA interference regulate nucleolar organization and repeated DNA stability. Nat Cell Biol, 9(1),25–35.
   PubMed Web of Science ®Google Scholar
• Pettersen HS, Galashevskaya A, Doseth B, et al. 2015. AID expression in B-cell lymphomas causes accumulation of genomic uracil and a distinct AID mutational signature. DNA Repair (Amst), 25, 60–71.
   PubMed Web of Science ®Google Scholar
• Pulito C, Donzelli S, Muti P, et al. 2014. microRNAs and cancer metabolism reprogramming: the paradigm of metformin. Ann Transl Med, 2(6), 58.
   Google Scholar
• Qin H, Suzuki K, Nakata M, et al. 2011. Activation-induced cytidine deaminase expression in CD4+ T cells is associated with a unique IL-10-producing subset that increases with age. PLoS One, 6(12), e29141.
   PubMed Web of Science ®Google Scholar
• Rawstron AC. 2013. Monoclonal B cell lymphocytosis–what does it really mean? Curr Hematol Malig Rep, 8(1),52–59.
   Google Scholar
• Robbiani DF, Bothmer A, Callen E, et al. 2008. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell, 135(6),1028–1038.
   Google Scholar
• Tang KF, Ren H. 2012. The role of dicer in DNA damage repair. Int J Mol Sci, 13(12),16769–16778.
   Google Scholar
• Unniraman S, Schatz DG. 2006. AID and Igh switch region-Myc chromosomal translocations. DNA Repair (Amst), 5(9–10), 1259–1264.
   Google Scholar
• Wu JF, Shen W, Liu NZ, et al. 2011. Down-regulation of Dicer in hepatocellular carcinoma. Med Oncol, 28(3),804–809.
   Google Scholar
• Yamane A, Resch W, Kuo N, et al. 2011. Deep-sequencing identification of the genomic targets of the cytidine deaminase AID and its cofactor RPA in B lymphocytes. Nat Immunol, 12(1),62–69.
   Google Scholar
• Zhu DX, Fan L, Lu RN, et al. 2012. Downregulated Dicer expression predicts poor prognosis in chronic lymphocytic leukemia. Cancer Sci, 103(5),875–881.
   Google Scholar